Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...

Sage Therapeutics Inc (SAGE) reports significant prescription growth for ZURZUVAE, despite a net loss and strategic ...

Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "We ...

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -7.59% and 11.20%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) is expected to announce its earnings results after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of ...

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...